Comprehensive Oncology Limited 08940397 false 2023-04-01 2024-03-31 2024-03-31 The principal activity of the company is Oncology services Digita Accounts Production Advanced 6.30.9574.0 true 08940397 2023-04-01 2024-03-31 08940397 2024-03-31 08940397 bus:Director1 1 2024-03-31 08940397 bus:Director2 1 2024-03-31 08940397 core:RetainedEarningsAccumulatedLosses 2024-03-31 08940397 core:ShareCapital 2024-03-31 08940397 core:CurrentFinancialInstruments 2024-03-31 08940397 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 08940397 core:FurnitureFittings 2024-03-31 08940397 core:OfficeEquipment 2024-03-31 08940397 bus:SmallEntities 2023-04-01 2024-03-31 08940397 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 08940397 bus:FullAccounts 2023-04-01 2024-03-31 08940397 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 08940397 bus:RegisteredOffice 2023-04-01 2024-03-31 08940397 bus:Director1 2023-04-01 2024-03-31 08940397 bus:Director1 1 2023-04-01 2024-03-31 08940397 bus:Director2 2023-04-01 2024-03-31 08940397 bus:Director2 1 2023-04-01 2024-03-31 08940397 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 08940397 core:FurnitureFittings 2023-04-01 2024-03-31 08940397 core:OfficeEquipment 2023-04-01 2024-03-31 08940397 countries:UnitedKingdom 2023-04-01 2024-03-31 08940397 2023-03-31 08940397 bus:Director1 1 2023-03-31 08940397 bus:Director2 1 2023-03-31 08940397 core:FurnitureFittings 2023-03-31 08940397 core:OfficeEquipment 2023-03-31 08940397 2022-04-01 2023-03-31 08940397 2023-03-31 08940397 bus:Director1 1 2023-03-31 08940397 bus:Director2 1 2023-03-31 08940397 core:RetainedEarningsAccumulatedLosses 2023-03-31 08940397 core:ShareCapital 2023-03-31 08940397 core:CurrentFinancialInstruments 2023-03-31 08940397 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 08940397 core:FurnitureFittings 2023-03-31 08940397 core:OfficeEquipment 2023-03-31 08940397 bus:Director1 1 2022-04-01 2023-03-31 08940397 bus:Director2 1 2022-04-01 2023-03-31 08940397 bus:Director1 1 2022-03-31 08940397 bus:Director2 1 2022-03-31 iso4217:GBP xbrli:pure

Registration number: 08940397

Comprehensive Oncology Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 March 2024

 

Comprehensive Oncology Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 6

 

Comprehensive Oncology Limited

Company Information

Directors

Dr P D Correa

Mrs S S Correa

Registered office

Oakmoore Court
Kingswood Road
Hampton Lovett
Droitwich
Worcs
WR9 0QH

Accountants

Ballards LLP
Chartered Accountants
Oakmoore Court
11C Kingswood Road
Hampton Lovett
Droitwich
Worcestershire
WR9 0QH

 

Comprehensive Oncology Limited

(Registration number: 08940397)
Balance Sheet as at 31 March 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

2,801

2,533

Current assets

 

Debtors

5

533,732

507,933

Cash at bank and in hand

 

63,740

53,059

 

597,472

560,992

Creditors: Amounts falling due within one year

6

(34,162)

(87,764)

Net current assets

 

563,310

473,228

Net assets

 

566,111

475,761

Capital and reserves

 

Called up share capital

100

100

Retained earnings

566,011

475,661

Shareholders' funds

 

566,111

475,761

For the financial year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 30 July 2024 and signed on its behalf by:
 

.........................................
Dr P D Correa
Director

.........................................
Mrs S S Correa
Director

 
 

Comprehensive Oncology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

1

General information

The company is a private company limited by share capital, incorporated in United Kingdom.

The address of its registered office is:
Oakmoore Court
Kingswood Road
Hampton Lovett
Droitwich
Worcs
WR9 0QH
England

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Comprehensive Oncology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixture and fittings

33% on reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

 

Comprehensive Oncology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2023 - 2).

4

Tangible assets

Fixtures and fittings
£

Office equipment
£

Total
£

Cost or valuation

At 1 April 2023

1,661

8,042

9,703

Additions

-

1,580

1,580

At 31 March 2024

1,661

9,622

11,283

Depreciation

At 1 April 2023

960

6,210

7,170

Charge for the year

175

1,137

1,312

At 31 March 2024

1,135

7,347

8,482

Carrying amount

At 31 March 2024

526

2,275

2,801

At 31 March 2023

701

1,832

2,533

5

Debtors

Note

2024
£

2023
£

Trade debtors

 

11,433

-

Amounts owed by related parties

7

274,666

209,666

Other debtors

 

247,633

298,267

   

533,732

507,933

Included within the above are debtors falling due over 1 year of £274,666 (2023:£209,666).
 

 

Comprehensive Oncology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

6

Creditors

Note

2024
£

2023
£

Due within one year

 

Trade creditors

 

2,001

2,005

Other creditors

 

32,161

85,759

 

34,162

87,764

7

Related party transactions

Transactions with directors

2024

At 1 April 2023
£

Advances to director
£

Repayments by director
£

At 31 March 2024
£

Dr P D Correa

Loan to Directors

117,810

-

(25,316)

92,494

         
       

Mrs S S Correa

Loan to Director

117,810

-

(25,316)

92,494

         
       

 

2023

At 1 April 2022
£

Advances to director
£

At 31 March 2023
£

Dr P D Correa

Loan to Directors

-

117,810

117,810

       
     

Mrs S S Correa

Loan to Director

-

117,810

117,810